As back to school season approaches, Pilot Corporation of America (Pilot Pen) is working diligently to help empower students to excel and to overcome their greatest challenges during the school year. Bullying and cyberbullying are at an all time high, with nearly 1 out of 4 U.S. students having been bullied. Pilot Pen’s ongoing partnership with the nation’s leading anti-bullying prevention organization, STOMP Out Bullying is designed to help “Erase Bullying For Good,” for the fourth consecutive year. The goal of this campaign is to raise awareness of this serious issue, helping to ensure that parents, educators and students are aware of the valuable resources available to those in need of support. As part of the effort, Pilot is donating 10 cents from every specially-marked package of FriXion Clicker erasable gel ink pens purchased during the back to school period, to support STOMP Out Bullying. Pilot is committed to donating $325,000 to the organization.
To view the multimedia release go to:
https://www.multivu.com/players/English/8342451-pilot-pen-stomp-out-erase-bullying-for-good/
The goal of the campaign by United Colors of Benetton, devised and created by Fabrica, is also to advocate international awareness of the need for concrete actions to support women and prevention programs, beginning with efforts to promote an education for young men and women that develops a culture based on recognition, respect for difference and equal opportunities.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7387451-benetton-un-end-violence-women/
The CDC Foundation, actor Idris Elba and a global team of African soccer stars, international health and aid organizations today announced the launch of Africa United, a global health communications campaign aimed at preventing the spread of Ebola in West Africa. Africa United will leverage campaign partners and celebrities to provide critical education and resources for the people of West Africa.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7390651-cdc-foundation-we-are-africa-united-ebola-health-workers/
Vigilant Solutions, a global intelligence and analytics company serving law enforcement agencies, announced today BallisticSearch™, a new product providing law enforcement agencies with faster and more efficient cartridge case analysis, will be unveiled at the upcoming International Association of Chiefs of Police Conference, October 21st – 24th in Philadelphia. BallisticSearch includes portable image capture hardware, cartridge case capture software and ballistics comparison technology. The solution enables agencies to quickly compare evidence from crime scenes to help generate more investigative leads, and potentially identify more suspects and the firearms they use.
Developed using the company’s image analysis and technology expertise, BallisticSearch is designed to be the most efficient system available for analyzing ballistic evidence in both 2D and 3D format. BallisticSearch can process evidence in minutes, while other systems can take hours to process the same evidence. BallisticSearch’s faster analysis will have a huge impact on reducing backlogs. With faster comparisons and potential links established, agencies can generate strong investigative leads boosting their ability to solve crimes more quickly, in some cases right from the crime scene. This will help agencies establish a comprehensive ballistic collection program and ultimately reduce crime rates.
To view the multimedia release go to:
https://www.multivu.com/players/English/8134351-vigilant-solutions-ballisticsearch-faster-analysis/
Breast cancer now represents one in four of all cancers in women worldwide and touches lives every day. While experiences with the disease may vary, the desire to defeat breast cancer is universal. This year, in honor of a shared vision for a world without this disease, The Estée Lauder Companies’ Breast Cancer Awareness (BCA) Campaign celebrates the power of global solidarity by encouraging people around the world to “Take Action Together to Defeat Breast Cancer.” The 2016 BCA Campaign invites women, men and families to draw inspiration from one another and unite in action on BCAcampaign.com and social media, while supporting lifesaving breast cancer research.
Over the past two decades, The Estée Lauder Companies’ BCA Campaign, launched by the late Evelyn H. Lauder, co-creator of the Pink Ribbon and founder of the Breast Cancer Research Foundation® (BCRF), has been a leading voice for breast cancer awareness around the world, igniting a global movement that has helped save millions of lives and fund innovative breast cancer research. Today, The BCA Campaign is active in more than 70 countries and has raised more than $65 million to support global research, education and medical services, with more than $50 million funding 200 BCRF medical research grants worldwide over the past 22 years. These funds help accelerate critical research across wide-ranging areas such as tumor biology, heredity and ethnicity, lifestyle and prevention, treatment, survivorship and metastasis. Around the world, The BCA Campaign partners with more than 60 breast cancer organizations focused on breast cancer research, education and medical services. This year, The BCA Campaign is committed to raising $6 million in support of its mission to defeat breast cancer through education and medical research.
To view the multimedia release go to:
http://www.multivu.com/players/English/7935851-estee-lauder-bca-campaign-2016/
Global biotherapeutics leader CSL Behring today announced that results were published in the New England Journal of Medicine (NEJM) from the COMPACT study, a pivotal Phase III study evaluating the safety and efficacy of CSL830 (a novel, investigational, self-administered, subcutaneous C1-Esterase Inhibitor [C1-INH] Human replacement therapy) for the prevention of HAE attacks. The study met its primary efficacy endpoint, significantly reducing the time-normalized number of HAE attacks. In addition, the study met its secondary endpoints, including the responder rate (patients who had at least a 50% reduction in their attack rate) and the number of rescue medication uses. If approved by the FDA, CSL830 would be the first and only subcutaneous preventative therapy for HAE.
To view the multimedia release go to:
https://www.multivu.com/players/English/8056151-csl-behring-subcutaneous-c1-esterase-inhibitor-hae-patients/
The European Head and Neck Society (EHNS) and the Make Sense Campaign, today announced the launch of the Third Annual Head and Neck Cancer Awareness week (21–25 September). Through the pan-European Awareness Week, the EHNS and Make Sense Campaign promote education on head and neck cancer risk factors, disease prevention and disease signs and symptoms for both patients and healthcare professionals.
“Each year 350,000 people are diagnosed with head and neck cancer across Europe, and over half will not be alive after five years. However, if diagnosed and treated earlier, patients can have an 80 – 90% survival rate.” said Professor René Leemans, President of the EHNS and Professor and Chief of Otolaryngology – Head and Neck Surgery at VU University Medical Centre. “Through the Make Sense Campaign we are educating people about the early signs of the disease and encouraging them to seek professional help in a timely manner. Additionally, we are advocating for the best possible standards of patient care so that their outcomes can be optimised once they have been diagnosed with the disease.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7628151-support-head-neck-cancer-patients/
Results from two national surveys of patients receiving chemotherapy and pharmacists, conducted by the Hematology/Oncology Pharmacy Association (HOPA) in collaboration with Eisai Inc.,* found that 83% of patients receiving chemotherapy who have experienced chemotherapy-induced nausea and vomiting (CINV) believe it is a side effect with which they must live. Results also showed that 95% of cancer patients surveyed believe that CINV has, at some point, had an impact on their daily lives. These national surveys are part of the Time to Talk CINV™ campaign, which aims to increase awareness among patients and caregivers about CINV prevention and the importance of speaking with their pharmacist and full healthcare team about this often preventable side effect.
“The survey results underscore the confusion patients who are undergoing chemotherapy have about CINV and the need for them to understand that there are ways to manage their symptoms so that they do not have to needlessly suffer with CINV,” said Scott Soefje, PharmD, MBA, BCOP, President, Hematology/Oncology Pharmacy Association (HOPA) and Director of Pharmacy at the University Medical Center Brackenridge in Austin, TX. “It is imperative that patients discuss CINV prevention early in treatment and with all members of the health care team, including pharmacists.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7560331-time-to-talk-cinv/
Kelli Calabrese is a fitness, nutrition and lifestyle expert encouraging those who desire to be their best spirit, mind and body. Through her speaking, books and solutions, she inspires all to enjoy a fit energized body, sharp mind and joy-filled lifestyle. In addition to this, Kelli is business owner, international presenter, editor and mother of two preschoolers. Her passion for fitness began when Calabrese joined her first group fitness class at the age of thirteen.
For over 14 years Kelli owned and operated fitness centers and corporate fitness facilities for clients such as Calvin Klein, Beneficial Insurance and Nabisco. Kelli was the lead fitness expert for eDiets and eFitness for 3 years and continues to contribute articles to their e-zine. She has written over 100 articles or has been interviewed by companies such as WebMD, Prevention, Women's Day, Women's World, New York Times, New York Post, iVillage, iParenting, Shape, Martha Stewart, Beauty and Lace and more. Kelli has appeared on Fit week and had been interviewed on fitness and nutrition related topics for Comcast stations.
The Ad Council’s I Am A Witness campaign is bringing together the top digital companies in the teen space for the second iteration of the award-winning and unprecedented effort aimed at transforming the “silent majority” of kids who witness bullying each day from passive bystanders into a united, empowered and active collective against bullying. The campaign is the first to create an anti-bullying emoji adopted by Unicode and natively available on nearly all smartphones across the world. There will be activations throughout the month of October to coincide with Bullying Prevention Month.
To view the multimedia release go to:
http://www.multivu.com/players/English/7933951-ad-council-i-am-a-witness-anti-bullying/
Building on a successful campaign that helped hundreds of thousands of Americans learn their risk of developing type 2 diabetes through campaign messaging and an online risk test, the first-of-its-kind initiative to raise national awareness of prediabetes returns with an entertaining new approach. The new campaign, launching today, encourages viewers to take a one-minute prediabetes risk test to know where they stand and discover how they can decrease their risk of developing type 2 diabetes — and it does so with some adorable helpers.
More than one in three American adults has prediabetes — a serious health condition that often leads to type 2 diabetes and other significant health conditions like blindness, heart attack or stroke. According to newly released CDC data, however, nearly 90 percent of the 84 million people with prediabetes don’t know they have it and aren’t aware of the long-term risks to their health. Currently, about 30 million Americans are living with diabetes.
To view the multimedia release go to:
https://www.multivu.com/players/English/8142351-ad-council-prediabetes/
The number of vehicles earning either of two awards from the Insurance Institute for Highway Safety has jumped to 71 from 39 this time last year, giving consumers more choices for optimum protection in crashes. The number of winners in the top tier — TOP SAFETY PICK+ — has increased by 11 for 2015, despite a tougher standard for front crash prevention.
While the bar has been raised for TOP SAFETY PICK+, the criteria for TOP SAFETY PICK are unchanged from 2014: a good or acceptable rating in the challenging small overlap front test and a good rating in each of the Institute's four other crashworthiness evaluations — moderate overlap front, side, roof strength and head restraints. The 2015 TOP SAFETY PICK+ designation is awarded to vehicles that meet those criteria and also have an available front crash prevention system that earns an advanced or superior rating.
